AMSilk has raised EUR 52 million in funding to scale the industrial production of its silk-based protein materials. The investment round was led by ATHOS (AT Newtec) with additional participation from MIG Capital and Novo Holdings. Of the total amount, EUR 30 million is equity, while EUR 22 million comes in the form of convertible bonds. AMSilk plans to use the funds to increase production capacity and meet the rising global demand for its innovative biomaterials. The company has already established long-term production agreements with industrial partners and has dedicated production facilities in operation at key partner sites.

AMSilk reprograms microorganisms to produce silk-based proteins, which are then processed into various products such as powders, hydrogels, fibers, and coatings. These materials are biodegradable and suitable for use in industries like textiles, automotive, and consumer care. The company's partnerships with global brands and industrial manufacturers like Evonik and Ajinomoto have helped to validate the commercial potential of AMSilk's technology. With the support of investors, AMSilk is on a path to accelerate production and meet the increasing demand for its biomaterials, demonstrating its ability to scale and innovate in the biotech materials industry.